Core Insights - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [4] Group 1: Upcoming Events - Thomas Zindrick, President, CEO, and Chairman, along with Matt Pulisic, CFO, will discuss clinical-stage programs and milestones at the Citizens Life Sciences Conference on May 7-8, 2025 [1] - The conversation is scheduled for May 8, 2025, at 1:30 p.m. ET, and a webcast link will be available for the event [2] - The company will also hold one-on-one meetings during the conference for institutional investors interested in engaging with management [3] Group 2: Clinical Trials - Olvi-Vec is currently being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a Phase 3 trial for platinum-resistant/refractory ovarian cancer, and VIRO-25, a Phase 2 trial for non-small-cell lung cancer [4] - Additionally, Olvi-Vec is being assessed in a China-based Phase 1b trial for recurrent small-cell lung cancer [4] Group 3: Company Overview - Genelux's discovery and development efforts are centered around its proprietary CHOICE™ platform, which has led to a library of engineered oncolytic vaccinia virus immunotherapeutic candidates, including Olvi-Vec [4]

Core Insights - Genelux Corporation has reached alignment with the U.S. FDA on key elements of the approval pathway for Olvi-Vec in treating platinum-resistant/refractory ovarian cancer [1][4] - The company reported a net loss of $29.9 million for the year ending December 31, 2024, compared to a net loss of $28.3 million in 2023 [15][21] - Genelux has strengthened its management team and balance sheet, positioning itself for future growth and clinical development [2][7] Pipeline Highlights - The ongoing Phase 3 OnPrime/GOG-3076 trial is focused on platinum-resistant/refractory ovarian cancer, with a primary endpoint of progression-free survival (PFS) [3] - The FDA indicated that an interim analysis of overall survival (OS) should be planned alongside the primary PFS analysis, which could support traditional approval if a meaningful PFS advantage is demonstrated [4] - The trial aims to enroll enough patients to achieve 127 events, with topline data expected in the first half of 2026 [5] Clinical Trials Updates - Preliminary data from the Phase 1b/2 Olvi-Vec-SCLC-202 trial showed a 71% disease control rate in patients with extensive small cell lung cancer [11] - The Phase 2 VIRO-25 trial is actively enrolling patients with recurrent non-small cell lung cancer, with interim data anticipated in the second half of 2025 [6] Financial Overview - The company closed an underwritten offering of 3 million shares at $3.50 per share, raising approximately $10.5 million for working capital and clinical development [8][10] - As of December 31, 2024, cash, cash equivalents, and short-term investments totaled $30.9 million, providing a runway into the first quarter of 2026 [12] - Research and development expenses increased to $19.0 million in 2024 from $12.8 million in 2023, primarily due to higher clinical trial costs [13] Management Changes - Matt Pulisic has joined Genelux as the new Chief Financial Officer, bringing over 19 years of experience in the biopharmaceutical industry [7]

[Special Note Regarding Forward-Looking Statements](index=3&type=section&id=SPECIAL%20NOTE%20REGARDING%20FORWARD-LOOKING%20STATEMENTS) This section cautions that the Annual Report contains forward-looking statements subject to known and unknown risks and uncertainties, which the company does not publicly update - The report contains forward-looking statements regarding future results, business strategy, R&D costs, clinical trials for Olvi-Vec, regulatory approvals, commercialization, pricing, reimbursement, strategic collaborations, and financing needs[11](index=11&type=chunk) - These statements are subject to known and unknown risks, uncertainties, and important factors that may cause actual results to be materially different from those expressed or implied[11](index=11&type=chunk) - The company operates in an evolving environment with new risk factors emerging, and it undertakes no obligation to publicly update or revise any forward-looking statements, except as required by applicable law[12](index=12&type=chunk) [Summary of Risks Associated with Our Business](index=4&type=section&id=SUMMARY%20OF%20RISKS%20ASSOCIATED%20WITH%20OUR%20BUSINESS) This section summarizes material risks including financial losses, financing needs, early-stage product development, regulatory complexities, and intellectual property challenges - The company has incurred **significant losses** since inception and anticipates continued losses, potentially never achieving profitability[17](index=17&type=chunk) - Substantial additional financing is required for Olvi-Vec development and future product candidates; failure to obtain it could force delays or termination of programs[17](index=17&type=chunk) - Product candidates are in preclinical/clinical stages, not approved for sale, and may never receive regulatory approval or become commercially viable[17](index=17&type=chunk) - The company's sole clinical product candidate is Olvi-Vec; its failure would adversely affect the business[17](index=17&type=chunk) - Compliance with federal and state healthcare laws, including fraud and abuse laws, is critical; non-compliance could lead to substantial penalties[17](index=17&type=chunk) - Inability to obtain, maintain, and protect intellectual property rights could harm the company's competitive position[17](index=17&type=chunk) [PART I](index=5&type=section&id=PART%20I) [Item 1. Business](index=5&type=section&id=Item%201.%20Business) This section provides a comprehensive overview of Genelux Corporation's business, including its focus on oncolytic viral immunotherapies, its lead product candidate Olvi-Vec, its proprietary discovery platform, clinical pipeline, strategic objectives, manufacturing capabilities, and intellectual property [Overview](index=5&type=section&id=OVERVIEW) Genelux is a late clinical-stage biopharmaceutical company specializing in next-generation oncolytic viral immunotherapies for aggressive solid tumors, with Olvi-Vec as its lead product - Genelux is a late clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies for aggressive solid tumors[18](index=18&type=chunk) - Olvi-Vec (olvimulogene nanivacirepvec) is the lead product candidate, a proprietary, modified strain of the vaccinia virus (VACV)[18](index=18&type=chunk) - The company utilizes its proprietary CHOICE selection technology and discovery and development platform to create an extensive library of oncolytic VACV immunotherapeutic product candidates[19](index=19&type=chunk) - Genelux has a cGMP manufacturing facility in San Diego, California, for clinical trials and initial commercial launch of Olvi-Vec, if approved[22](index=22&type=chunk) [Pipeline](index=6&type=section&id=PIPELINE) Genelux's pipeline is centered on Olvi-Vec, with ongoing clinical trials for various indications, including Phase 3 for Ovarian Cancer and Phase 2 for Non-Small Cell Lung Cancer | Olvi-Vec Route | Indication | Design | Phase 3 | Anticipated Milestones | Collaborators | |---|---|---|---|---|---| | Regional | Ovarian Cancer (platinum-resistant/refractory) | Olvi-Vec (i.pe) +Platinum-based regimen | Ph3 OnPrime/GOG-3076 Trial Actively Enrolling | Topline results expected in 1H, 2026 | (Cooperative Group. U.S-based trial) | | Systemic | Non-Small Cell Lung Cancer (recurrent/platinum-ICI failure) | Olvi-Vec (IV) +Platinum/Checkpoint inhibitor-based regimen | Ph2 Actively Enrolling | Interim readout expected 2H, 2025 | U.S-based trial | | Systemic | Small Cell Lung Cancer (recurrent/platinum failure) | Olvi-Vec (IV) +Platinum-based regimen | Ph1b/2 Actively Enrolling | Interim readout (updated data) expected in 2H, 2025 | NEWSGARA (Greater China-based trials) | | Systemic | Ovarian Cancer (recurrent/platinum failure) | Olvi-Vec (IV) +Platinum-based regimen | Ph1b/2 Regulatory Submission | Interim readout (updated data) expected in 2H, 2025 | NEWSGARA (Greater China-based trials) | | Systemic | Pancreatic Cancer (recurrent) | Olvi-Vec (IV) +Adoptive Cell Therapy | Regulatory Submission | | (Worldwide Rights Ex-Greater China) | [Our Strategy](index=6&type=section&id=OUR%20STRATEGY) Genelux's strategy focuses on advancing Olvi-Vec through late-stage clinical development, supporting its partner Newsoara, preparing for US launch, strengthening manufacturing, leveraging its CHOICE platform, and seeking additional collaborations - Advance lead product candidate, Olvi-Vec, through late-stage clinical development focused on platinum re-sensitization and seek regulatory approval. Phase 3 OnPrime trial for PRROC initiated enrollment in Q3 2022, and Phase 2 VIRO-25 trial for recurrent NSCLC initiated enrollment in Q4 2024[25](index=25&type=chunk) - Support clinical and commercial development of Olvi-Vec with strategic partner Newsoara in China, including co-sponsored Phase 1b/2 clinical trial in SCLC and planned Phase 2 VIRO-25 and ovarian cancer trials[25](index=25&type=chunk) - Prepare for US launch in ovarian cancer by expanding preliminary commercial strategy initiatives[29](index=29&type=chunk) - Broaden and strengthen internal manufacturing capabilities using the in-house cGMP manufacturing facility in San Diego[29](index=29&type=chunk) - Leverage the CHOICE discovery platform to build a portfolio of oncology product candidates and progress them into clinical development[29](index=29&type=chunk) - Seek additional development and commercial collaborations for Olvi-Vec and other product candidates, retaining US rights and pursuing strategic partnerships in other geographic areas[29](index=29&type=chunk) [The Genelux Approach](index=7&type=section&id=THE%20GENELUX%20APPROACH) Genelux's approach uses oncolytic vaccinia virus (VACV) as the backbone of its proprietary CHOICE discovery platform to develop immunotherapies like Olvi-Vec, designed to selectively kill tumor cells and induce a robust immune response - Olvi-Vec utilizes VACV as the backbone of the proprietary CHOICE discovery platform, which allows for rapid development of new product candidates[26](index=26&type=chunk)[27](index=27&type=chunk) - The company has an extensive portfolio of over **500 different versions of VACV** armed with more than **110 transgenes**, with Olvi-Vec being the most clinically advanced[28](index=28&type=chunk) - Oncolytic immunotherapy product candidates are 'off-the-shelf' personalized immunotherapies, designed to selectively kill tumor cells and induce a robust immune response against a patient's tumor neoantigens[30](index=30&type=chunk) - Olvi-Vec's mechanism of action involves selectively replicating in tumor cells, converting the tumor microenvironment to an immunoreactive state, causing tumor cell necrosis, and enhancing neoantigen presentation to stimulate a tumor-specific immune response[33](index=33&type=chunk)[34](index=34&type=chunk) [Development Programs](index=9&type=section&id=DEVELOPMENT%20PROGRAMS) Genelux is actively advancing Olvi-Vec through several development programs, including a Phase 3 registration trial for platinum-resistant/refractory ovarian cancer (PRROC) and systemic administration trials for recurrent lung cancers [Platinum Resistant/Refractory Ovarian Cancer (PRROC)](index=9&type=section&id=Platinum%20Resistant%2FRefractory%20Ovarian%20Cancer) Genelux initiated a Phase 3 OnPrime registration trial for Olvi-Vec in PRROC, following positive Phase 1b/2 data showing re-sensitization to platinum-based therapy and significantly improved outcomes - A Phase 3 OnPrime registration trial for Olvi-Vec in PRROC initiated enrollment in Q3 2022, targeting a broad and underserved patient population with a **2:1 randomization design**[37](index=37&type=chunk) - The FDA confirmed that a clinically meaningful PFS advantage without OS decrement could support traditional approval, and recommended a pre-BLA meeting after trial completion[38](index=38&type=chunk) - Phase 2 data showed Olvi-Vec re-sensitized PRROC patients to platinum-based therapy, with a **54% ORR (RECIST 1.1)**, **11.0 months median PFS**, and **15.7 months median OS**, significantly outperforming historical comparisons (<20% ORR, <4 months PFS, <12 months OS)[43](index=43&type=chunk)[44](index=44&type=chunk) Phase 2 PRROC Clinical Trial Efficacy Endpoints (All Patients, n=27) | Endpoint | Value (95% CI) | |---|---| | ORR by RECIST 1.1 | 54% (33 - 74) | | Duration of Response | 7.6 mos (3.7 - 9.6) | | ORR by CA-125 | 85% (65 - 96) | | Median PFS | 11.0 mos (6.7 - 13.0) | | Median Overall Survival (OS) | 15.7 mos (12.3 - 23.8) | [Systemic Administration](index=12&type=section&id=Systemic%20Administration) Genelux is pursuing systemic administration of Olvi-Vec for recurrent lung cancers, with a Phase 2 NSCLC trial initiated in Q4 2024 and promising preliminary data from an SCLC trial in China - Recurrent lung cancers (SCLC and NSCLC) were selected for intravenous Olvi-Vec delivery due to promising preclinical and clinical data and the 'first pass effect' to the lungs[53](index=53&type=chunk) - Phase 2 VIRO-25 trial for recurrent NSCLC in the US initiated enrollment in Q4 2024, with interim results expected in 2H 2025; Newsoara is expected to fund and add sites in China[56](index=56&type=chunk) - A co-sponsored Phase 1b/2 clinical trial for recurrent SCLC in China is ongoing, with interim results in Q1 2025 supporting Olvi-Vec as a platinum re-sensitizing agent[58](index=58&type=chunk)[61](index=61&type=chunk) - Preliminary SCLC data showed a **71% disease control rate** among evaluable participants, with tumor reductions up to **79%**, and a manageable safety profile[62](index=62&type=chunk) [Pancreatic Cancer](index=14&type=section&id=Pancreatic%20Cancer) Genelux, through its V2ACT joint venture, is developing V2ACT Immunotherapy for pancreatic cancer, combining Olvi-Vec with neoantigen-primed adoptive cell therapy, with an IND filed but no clinical trial yet scheduled - V2ACT Immunotherapy, a joint venture with TVAX, combines an oncolytic virus (Olvi-Vec) and neoantigen-primed adoptive cell therapy (NACT) for cancer[63](index=63&type=chunk) - The scientific rationale is that Olvi-Vec enhances the effects of adoptively transferred neoantigen-specific effector T cells by modulating the immune microenvironment[65](index=65&type=chunk) - An IND application for V2ACT Immunotherapy as a treatment for newly-diagnosed, surgically-resectable pancreatic cancer was filed in October 2020, but a clinical trial is not yet scheduled[66](index=66&type=chunk) [Additional Potential Indications for Olvi-Vec](index=15&type=section&id=Additional%20Potential%20Indications%20for%20Olvi-Vec) Genelux believes preclinical and clinical data support broad development of Olvi-Vec for various liquid and solid tumors, with future plans for intravenous delivery and potential basket or frontline ovarian cancer trials - Preclinical and clinical data support broad development of Olvi-Vec in patients with liquid or metastatic solid tumors, as monotherapy or in combination[68](index=68&type=chunk) - The company plans to expand its clinical development program by pursuing additional indications via intravenous delivery, selecting from over **20 major human cancers**[69](index=69&type=chunk) - Potential program expansions include basket trials for refractory/intolerant lung cancer patients (primary or metastatic) and frontline ovarian cancer studies, as suggested by the FDA[70](index=70&type=chunk) [Terms of Certain License Agreements](index=15&type=section&id=TERMS%20OF%20CERTAIN%20LICENSE%20AGREEMENTS) Genelux has entered into key license agreements, including an exclusive license with Newsoara BioPharma for Olvi-Vec in China and a joint venture with TVAX Therapeutics (V2ACT) for V2ACT Immunotherapy [Newsoara Biopharma Co., Ltd. Agreement](index=15&type=section&id=Newsoara%20Biopharma%20Co.,%20Ltd.%20Agreement) Genelux granted Newsoara an exclusive license for Olvi-Vec in China, receiving $11.0 million in upfront and milestone payments, with potential for up to $160.5 million in additional milestones and mid-single-digit to mid-teens royalties - Genelux granted Newsoara an exclusive license to research, develop, and commercialize Olvi-Vec in China for all human diagnostic, prophylactic, and therapeutic uses[72](index=72&type=chunk) Newsoara License Agreement Financials | Item | Amount (USD) | |---|---| | Aggregate payments received to date | **$11.0 million** (upfront + milestone) | | Additional development and commercial milestone payments | Up to **$160.5 million** | | Royalties on net sales | Mid-single-digit to mid-teens percentage range | - Newsoara is obligated to use commercially reasonable efforts for development and commercialization, and is responsible for all associated costs, including funding a multi-center Phase 2 clinical trial for Olvi-Vec in NSCLC[75](index=75&type=chunk) [V2ACT Joint Venture](index=16&type=section&id=V2ACT%20Joint%20Venture) Genelux formed V2ACT Therapeutics as a 50/50 joint venture with TVAX, granting V2ACT worldwide, non-exclusive, royalty-free licenses for combined virus and T-cell therapies, with V2ACT solely responsible for all development and commercialization costs - V2ACT Therapeutics, LLC was formed in January 2019 as a **50/50 joint venture** with TVAX Biomedical Inc. to develop and commercialize V2ACT Immunotherapy[78](index=78&type=chunk) - Genelux granted V2ACT a worldwide, non-exclusive, fully paid, royalty-free license for its proprietary oncolytic virus (Licensed Virus(es)) for combination cancer treatments[80](index=80&type=chunk) - V2ACT is solely responsible for all research, development, manufacturing, and commercialization activities and costs for the Products[80](index=80&type=chunk) [Operations](index=17&type=section&id=OPERATIONS) Genelux's operations include establishing its own cGMP manufacturing facility, relying on third parties for raw materials and services, and building sales and marketing capabilities for future US market entry [Manufacturing and Distribution](index=17&type=section&id=Manufacturing%20and%20Distribution) Genelux operates its own cGMP manufacturing facility in San Diego and has leased a second building for future expansion, while relying on third-party suppliers and contract laboratories for raw materials, testing, and distribution - Genelux operates its own **7,569 square-foot cGMP manufacturing facility** in San Diego, California, for clinical trials and commercial launch supplies[82](index=82&type=chunk) - A second **6,755 square-foot building** in the same location has been leased for future laboratory capabilities and administrative offices[83](index=83&type=chunk) - The company relies on agreements with raw material and component suppliers, contract laboratories for testing, and a third party for labeling, packaging, and distribution of clinical material[84](index=84&type=chunk) [Sales and Marketing](index=18&type=section&id=Sales%20and%20Marketing) Genelux currently lacks sales, marketing, or commercialization capabilities as no products are approved, but plans to build this infrastructure for independent US commercialization and international partnerships upon approval - None of the company's product candidates have been approved for sale, and it currently lacks sales, marketing, or commercialization capabilities[86](index=86&type=chunk) - If product candidates receive marketing approval, Genelux intends to commercialize them independently or jointly with partners in the United States and other geographies, building the necessary infrastructure over time[86](index=86&type=chunk) [Intellectual Property](index=18&type=section&id=INTELLECTUAL%20PROPERTY) Genelux protects its proprietary technologies through patents, trademarks, copyrights, and trade secrets, with a portfolio including 11 issued U.S. patents and 9 issued foreign patents as of December 31, 2024 [Patents](index=18&type=section&id=Patents) Genelux relies on patents to protect its technology and product candidates, navigating complex U.S. and international patent systems, with a portfolio including 11 issued U.S. patents and 9 issued foreign patents as of December 31, 2024 - The U.S. patent system involves provisional and non-provisional applications, with patents generally effective for **20 years** from the earliest non-provisional filing date, potentially extended by FDA regulatory review or USPTO delays[88](index=88&type=chunk)[89](index=89&type=chunk) - The patentability and claim breadth for protein-based biologics remain unsettled, and changes in patent laws or interpretations can diminish protection[90](index=90&type=chunk) - As of December 31, 2024, the patent portfolio consisted of **11 issued U.S. patents**, **1 pending U.S. patent application**, **9 issued foreign patents**, **7 pending foreign patent applications**, and one PCT application, covering current and future products and methods of use[92](index=92&type=chunk) [Trade Secrets](index=19&type=section&id=Trade%20Secrets) Genelux protects its proprietary information and know-how through trade secrets, relying on confidentiality and invention assignment agreements, but faces risks of breaches or independent discovery by competitors - The company relies on trade secrets and know-how, protected by confidentiality agreements with collaborators, employees, and consultants, and invention assignment agreements with employees[93](index=93&type=chunk) - Agreements may be breached, and trade secrets could become known or independently discovered by competitors, for which adequate remedies may not exist[93](index=93&type=chunk)[91](index=91&type=chunk) [Trademarks](index=19&type=section&id=Trademarks) Genelux considers its trademarks and trade names important for brand recognition, with 'Genelux' registered in several countries and 'CHOICE' as an unregistered trademark - 'Genelux' is an issued trademark registration in the European Union, United Kingdom, China, and other countries[95](index=95&type=chunk) - The unregistered trademark includes 'CHOICE'[96](index=96&type=chunk) [Competition](index=19&type=section&id=COMPETITION) Genelux faces intense competition in the biotechnology and pharmaceutical industries from various entities developing cancer therapies, including oncolytic viral immunotherapies, other immunotherapies, and traditional treatments [Competition in Cancer Therapeutics](index=19&type=section&id=Competition%20in%20Cancer%20Therapeutics) The cancer therapeutics market is highly competitive, with numerous companies and institutions developing treatments across various modalities, including oncolytic viral immunotherapies, other immunotherapies, and traditional therapies - The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on proprietary rights[97](index=97&type=chunk) - Genelux faces significant competition from pharmaceutical, biopharmaceutical, and biotechnology companies, as well as universities and research institutions, many of which have greater resources[97](index=97&type=chunk) - Competition in cancer therapeutics includes oncolytic viral immunotherapies (e.g., Amgen's IMLYGIC, Daiichi Sankyo's DELYTACT), approved immunotherapy antibodies, cancer vaccines, cell-based therapies, therapies activating innate immunity, and traditional cancer therapies[101](index=101&type=chunk)[103](index=103&type=chunk) [PRROC Competition](index=21&type=section&id=PRROC) For platinum-resistant/refractory ovarian cancer (PRROC), Genelux competes with various marketed generic and brand-name chemotherapies and product candidates in late-stage development - Currently marketed products for ovarian cancer include generic chemotherapies (cisplatin, carboplatin, paclitaxel) and brand products like Abbvie's ELAHERE, Sanofi-Aventis's TAXOTERE, Roche/Genentech's AVASTIN, GSK's ZEJULA, and AstraZeneca's LYNPARZA[105](index=105&type=chunk) - Product candidates in registration trials or later development for PRROC include Relacorilant (Corcept Therapeutics), Raludotatug deruxtecan (Daiichi Sankyo), Anlotinib (Advenchen Laboratories), and Afureserib (Laekna Therapeutics)[105](index=105&type=chunk) [NSCLC Competition](index=21&type=section&id=NSCLC) In non-small cell lung cancer (NSCLC), Genelux faces competition from various chemotherapies and numerous product candidates in late-stage development targeting specific pathways - Chemotherapies for NSCLC include cisplatin, carboplatin, vinorelbine tartrate, paclitaxel, and brand products like Sanofi-Aventis's TAXOTERE and Eli Lilly's ALIMTA[104](index=104&type=chunk) - Product candidates in registration trials or later development for NSCLC target various mechanisms, including Checkpoint inhibitors (**17 candidates**), Tubulin inhibitors (**2**), KRAS inhibitors (**4**), EGFR inhibitors (**3**), DNA topoisomerase inhibitors (**4**), and VEGF inhibitors (**2**)[106](index=106&type=chunk) [SCLC Competition](index=22&type=section&id=SCLC) For small cell lung cancer (SCLC), current marketed products include topotecan hydrochloride and several immunotherapies, with numerous product candidates also in late-stage development - Currently marketed products for SCLC include topotecan hydrochloride, Amgen's IMDELLTRA, Jazz Pharmaceuticals' ZEPZELCA, Roche/Genentech's TECENTRIQ, AstraZeneca's IMFINZI, Merck's KEYTRUDA, and Bristol Myers Squibb's OPDIVO + YERVOY[107](index=107&type=chunk) - Product candidates in registration trials or later development for SCLC include Nibrozetone (EpicentRx), Tremelimumab (AstraZeneca), Ifinatamab deruxtecan (Daiichi Sankyo and Merck), Tifcemalimab (Junshi Biosciences), and Serplulimab (Shanghai Henlius Biotech)[110](index=110&type=chunk) [Generic Competition](index=23&type=section&id=Generic%20Competition) The BPCIA established an abbreviated pathway for biosimilar approval, granting 12 years of data exclusivity for original branded biological products, which Genelux anticipates for Olvi-Vec, though this exclusivity could be challenged or shortened - The BPCIA created an abbreviated pathway for biosimilar approval, establishing **12 years of data exclusivity** for original branded biological products approved under a BLA[111](index=111&type=chunk) - Olvi-Vec and other product candidates are biological products, and Genelux anticipates being awarded **12 years of data exclusivity** in the United States, up to **11 years in Europe**, and significant durations in other markets[112](index=112&type=chunk) - There is a risk that this exclusivity could be changed in the future due to congressional action, proposed budgets, or international trade agreements, or that the FDA may not consider Genelux's products as reference products[117](index=117&type=chunk) [Government Regulation and Product Approval](index=23&type=section&id=Government%20Regulation%20and%20Product%20Approval) The development and commercialization of biological products in the U.S. are extensively regulated by the FDA, involving a lengthy and costly process from preclinical testing to post-approval requirements, with expedited programs not guaranteeing success [U.S. Biological Products Development Process](index=23&type=section&id=U.S.%20Biological%20Products%20Development%20Process) The U.S. biological product development process is lengthy and expensive, requiring preclinical testing, IND submission, IRB/IBC approvals, and multi-phase human clinical trials, with extensive regulatory monitoring and potential delays - The U.S. biological product development process involves preclinical testing (GLP), IND application, IRB/IBC approval, human clinical trials (GCP), BLA submission, FDA review, facility inspections, and user fees[114](index=114&type=chunk)[115](index=115&type=chunk) - Clinical trials typically proceed through three sequential phases: Phase 1 (safety, dosage tolerance), Phase 2 (adverse effects, preliminary efficacy, optimal dosage), and Phase 3 (statistically confirm potency and safety for approval)[120](index=120&type=chunk)[127](index=127&type=chunk) - The FDA can place clinical trials on hold due to safety concerns, faulty design, or non-compliance, and sponsors must submit prompt safety reports for serious adverse events[117](index=117&type=chunk)[123](index=123&type=chunk) [Compliance with cGMP Requirements](index=26&type=section&id=Compliance%20with%20cGMP%20Requirements) Manufacturers of biological products must adhere to cGMP regulations, verified through periodic inspections, and failure to comply can lead to product restrictions, market withdrawal, or delays in BLA approval - Manufacturers of biological products must comply with cGMP regulations, including quality control, quality assurance, and maintenance of records and documentation[128](index=128&type=chunk) - Establishments must register with the FDA and state agencies and are subject to periodic, unannounced inspections to ensure cGMP compliance[128](index=128&type=chunk) - The FDA will not approve a BLA unless manufacturing processes and facilities comply with cGMP requirements and assure consistent product quality[128](index=128&type=chunk) [U.S. FDA Review and Approval Process](index=26&type=section&id=U.S.%20FDA%20Review%20and%20Approval%20Process) The FDA review and approval process for biological products involves submitting a BLA with extensive data, paying user fees, meeting pediatric study requirements, and undergoing thorough review, potentially including advisory committee input and facility inspections - A BLA, including preclinical and clinical data, CMC information, and proposed labeling, is submitted to the FDA for marketing approval[131](index=131&type=chunk) - BLAs generally require significant user fees under PDUFA, and pediatric data submission is mandated by PREA, with potential deferrals or waivers[132](index=132&type=chunk)[133](index=133&type=chunk) - The FDA conducts an in-depth review of the BLA, may refer it to an advisory committee, determines if a REMS is necessary, and inspects manufacturing and clinical sites before issuing an approval or complete response letter[135](index=135&type=chunk)[136](index=136&type=chunk)[137](index=137&type=chunk) [Expedited Development and Review Programs](index=28&type=section&id=Expedited%20Development%20and%20Review%20Programs) The FDA offers programs like Fast Track, Breakthrough Therapy, Priority Review, and Accelerated Approval to expedite development and review for product candidates treating serious conditions with unmet medical needs, though these do not guarantee approval - Fast Track designation expedites development and review for product candidates treating serious conditions with unmet medical needs, offering frequent FDA interactions and potential rolling review[141](index=141&type=chunk) - Breakthrough Therapy designation is for product candidates showing substantial improvement over existing therapies, including Fast Track features plus more intensive FDA interaction and expedited development/review[142](index=142&type=chunk) - Accelerated Approval may be granted for serious conditions based on surrogate endpoints, contingent on confirmatory clinical studies to verify clinical benefit[145](index=145&type=chunk) [Post-Approval Requirements](index=30&type=section&id=Post-Approval%20Requirements) After regulatory approval, biological products are subject to extensive and ongoing FDA requirements, including annual user fees, cGMP compliance, adverse event reporting, and strict adherence to labeling and promotional regulations, with non-compliance leading to significant penalties - Approved products are subject to ongoing annual program user fees, potential confirmatory studies, and rigorous cGMP compliance for manufacturing, quality control, and record-keeping[148](index=148&type=chunk)[149](index=149&type=chunk) - Post-approval requirements include reporting cGMP deviations, adverse effects, updated safety/efficacy information, and compliance with electronic record/signature requirements, with potential for official lot release by the FDA[150](index=150&type=chunk) - Manufacturers must comply with advertising and promotion requirements, including the prohibition of promoting off-label uses, with violations potentially leading to significant regulatory actions, fines, and criminal penalties[153](index=153&type=chunk)[154](index=154&type=chunk) [Other Healthcare Laws and Regulations](index=31&type=section&id=Other%20Healthcare%20Laws%20and%20Regulations) Genelux's business activities are subject to numerous federal and state healthcare laws beyond FDA regulations, including anti-kickback statutes, false claims laws, HIPAA, and physician payment transparency requirements, with non-compliance risking substantial penalties - Business activities are subject to federal and state healthcare laws, including the Anti-Kickback Statute, which prohibits remuneration to induce referrals or purchases under federal healthcare programs[157](index=157&type=chunk) - The federal civil and criminal false claims laws, including the False Claims Act, prohibit presenting false or fraudulent claims for federal funds[158](index=158&type=chunk) - HIPAA imposes requirements on healthcare benefit programs regarding privacy, security, and transmission of individually identifiable health information[158](index=158&type=chunk) - The Physician Payments Sunshine Act requires manufacturers to report payments or transfers of value to physicians and teaching hospitals[158](index=158&type=chunk) - Non-compliance with these laws can lead to significant civil, criminal, and administrative penalties, damages, fines, imprisonment, and exclusion from government-funded healthcare programs[159](index=159&type=chunk) [Coverage and Reimbursement](index=33&type=section&id=Coverage%20and%20Reimbursement) The commercial success of Genelux's products depends on obtaining adequate coverage and reimbursement from third-party payors, a process that is uncertain, time-consuming, and costly, potentially limiting net revenue and profitability - Sales of approved product candidates depend on the availability of coverage and adequate reimbursement from third-party payors, including government programs, managed care, and private insurers[160](index=160&type=chunk) - Third-party payors are increasingly reducing reimbursements, limiting coverage to specific formularies, and implementing cost-containment programs, including price controls[160](index=160&type=chunk) - Obtaining coverage and reimbursement may require expensive pharmacoeconomic studies to demonstrate medical necessity and cost-effectiveness, with no assurance of consistent or adequate rates[162](index=162&type=chunk) - Unfavorable coverage policies and reimbursement rates, or increased pressure from managed care, could significantly reduce revenues and prevent profitability[163](index=163&type=chunk) [Health Reform](index=34&type=section&id=Health%20Reform) U.S. and foreign health reform initiatives, such as the ACA and IRA, significantly impact the biopharmaceutical industry by aiming to contain costs and control drug pricing, creating regulatory uncertainty that could affect profitability - The ACA and other health reform measures aim to contain healthcare costs, improve quality, and expand access, significantly affecting the biopharmaceutical industry[166](index=166&type=chunk)[167](index=167&type=chunk) - The Inflation Reduction Act (IRA) establishes a Drug Price Negotiation Program for certain high-expenditure biologics under Medicare Parts B and D, and imposes rebates for price increases exceeding inflation[168](index=168&type=chunk)[170](index=170&type=chunk) - The U.S. Supreme Court's Loper Bright decision overturned the Chevron doctrine, potentially leading to additional legal challenges to federal agency regulations, including the FDA, and increasing regulatory uncertainty[171](index=171&type=chunk) - State-level legislation and regulations are also increasing to control pharmaceutical pricing, including importation programs, which could adversely affect product pricing and reimbursement[173](index=173&type=chunk) [Data Privacy and Security](index=36&type=section&id=Data%20Privacy%20and%20Security) Genelux is subject to stringent and evolving data privacy and security obligations, including federal and international laws, contractual requirements, and industry standards, with non-compliance or security incidents risking regulatory investigations, litigation, fines, and reputational harm - The company processes confidential and sensitive information, including personal data and intellectual property, making it subject to numerous data privacy and security obligations[175](index=175&type=chunk) - Compliance is required with U.S. laws like HIPAA (for protected health information) and the California Consumer Privacy Act (CCPA), as well as international regulations like the EU GDPR and UK GDPR[175](index=175&type=chunk)[176](index=176&type=chunk) - Cyber-attacks, malicious activity, and personnel misconduct pose threats to information systems and data, with potential for significant disruptions, data loss, reputational harm, and regulatory actions[179](index=179&type=chunk) - The use of generative AI technologies by employees could lead to additional compliance costs, regulatory investigations, and lawsuits[177](index=177&type=chunk) [Additional Regulation](index=37&type=section&id=Additional%20Regulation) Genelux is subject to environmental, health, and safety laws governing hazardous substances and waste, and must comply with the U.S. Foreign Corrupt Practices Act (FCPA) and similar foreign anti-corruption laws, with violations leading to criminal and civil penalties - The company is subject to federal and state environmental, health, and safety laws (e.g., OSHA, RCRA, TSCA) governing hazardous substances and waste, with potential liability for damages and fines[180](index=180&type=chunk) - The U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. corporations from engaging in corrupt activities to obtain or retain business abroad, including interactions with foreign healthcare professionals[181](index=181&type=chunk) - Violations of the FCPA or equivalent foreign laws can result in criminal and civil fines, imprisonment, disgorgement, and suspension from government contracts[181](index=181&type=chunk) [Human Capital Resources](index=37&type=section&id=Human%20Capital%20Resources) Genelux prioritizes attracting and retaining top talent by fostering a safe and rewarding workplace with career development opportunities, competitive compensation, and robust benefits, with 24 employees as of December 31, 2024 - The company's human capital strategy focuses on attracting, motivating, and retaining highly qualified personnel through a rewarding workplace, career development, and strong compensation/benefits[183](index=183&type=chunk) Employee Count as of December 31, 2024 | Category | Number of Employees | |---|---| | Total Full-time and Part-time | **24** | | Research and Development & Manufacturing | **15** | | Management and Administrative | **9** | - The company monitors success using metrics like employee engagement, vacancy rates, promotion rates, and diversity representation, and uses stock-based compensation to attract and retain talent[185](index=185&type=chunk) [Corporate Information](index=38&type=section&id=Corporate%20Information) Genelux Corporation, incorporated in Delaware in September 2001, completed its IPO in January 2023 and is listed on the Nasdaq Capital Market under 'GNLX', operating as an 'emerging growth company' and 'smaller reporting company' - Genelux Corporation was incorporated in Delaware in September 2001, with principal executive offices in Westlake Village, California[186](index=186&type=chunk) - The company completed its IPO in January 2023, and its common stock is listed on the Nasdaq Capital Market under the symbol 'GNLX'[186](index=186&type=chunk) - Genelux is an 'emerging growth company' (EGC) until December 31, 2028, or earlier if certain conditions are met, and also a 'smaller reporting company' (SRC), benefiting from reduced reporting requirements[186](index=186&type=chunk) [Available Information](index=38&type=section&id=Available%20Information) Genelux Corporation is subject to the informational requirements of the Securities Exchange Act of 1934, filing Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K with the SEC, all available on the SEC's and company's websites - Genelux is subject to the informational requirements of the Exchange Act, filing Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K with the SEC[187](index=187&type=chunk) - Company filings are available free of charge on the SEC's website (http://www.sec.gov) and the company's website (www.genelux.com)[187](index=187&type=chunk)[188](index=188&type=chunk) [Item 1A. Risk Factors](index=39&type=section&id=Item%201A.%20Risk%20Factors) This section details the significant risks associated with investing in Genelux, covering financial position, product development, manufacturing, reliance on third parties, commercialization, intellectual property, government regulation, business operations, and common stock [Risks Related to our Financial Position and Need for Additional Capital](index=39&type=section&id=Risks%20Related%20to%20our%20Financial%20Position%20and%20Need%20for%20Additional%20Capital) Genelux has incurred significant and increasing losses, with an accumulated deficit of $251.4 million as of December 31, 2024, and anticipates continued losses, requiring substantial additional financing that may not be available on acceptable terms - Genelux has incurred significant operating losses since inception, with net losses of **$29.9 million in 2024** and **$28.3 million in 2023**, and an accumulated deficit of **$251.4 million** as of December 31, 2024[191](index=191&type=chunk)[598](index=598&type=chunk) - The company expects to incur significant and increasing operating losses for the foreseeable future and may never achieve or maintain profitability, requiring substantial additional financing[191](index=191&type=chunk)[194](index=194&type=chunk) - Failure to obtain necessary capital could force delays, limits, reductions, or termination of product development programs, commercialization efforts, or other operations[194](index=194&type=chunk) - The report of the independent registered public accounting firm included a 'going concern' explanatory paragraph, indicating substantial doubt about the company's ability to continue operations[207](index=207&type=chunk) - Two investors from private placements were contractually obligated to fund **$24.0 million**, but have not made these payments, which could exhaust available capital sooner than expected[197](index=197&type=chunk)[198](index=198&type=chunk) [Risks Related to Product Discovery, Development and Regulatory Approval](index=45&type=section&id=Risks%20Related%20to%20Product%20Discovery,%20Development%20and%20Regulatory%20Approval) Genelux's product development is highly uncertain, with Olvi-Vec being its only clinical-stage candidate based on a novel oncolytic VACV platform, facing risks of delays, unexpected adverse events, and difficulties in patient enrollment, with interim data not predicting final results - The success of the business depends on identifying and successfully developing product candidates from its CHOICE platform, but Olvi-Vec is currently the only one in clinical trials, and its failure could adversely affect other programs[209](index=209&type=chunk)[218](index=218&type=chunk)[220](index=220&type=chunk) - Product candidates are in preclinical and clinical stages, not approved for commercial sale, and may never receive regulatory approval or become commercially viable due to the lengthy, expensive, and uncertain development process[211](index=211&type=chunk)[224](index=224&type=chunk) - Delays in initiating or completing clinical trials can occur due to various factors, including inability to generate sufficient preclinical data, regulatory approval delays, slow patient enrollment, and manufacturing issues[226](index=226&type=chunk)[227](index=227&type=chunk) - Results of preclinical studies and early clinical trials may not be predictive of future clinical trial results, and interim/topline data are subject to change and audit[239](index=239&type=chunk)[243](index=243&type=chunk) - Serious adverse events or undesirable side effects during development or after approval could halt development, lead to regulatory refusal, or revocation of marketing authorizations[252](index=252&type=chunk) - The company anticipates using its product candidates in combination with third-party drugs/devices, over which it has limited control regarding supply, regulatory status, or approval[258](index=258&type=chunk)[259](index=259&type=chunk) [Risks Related to Manufacturing](index=68&type=section&id=Risks%20Related%20to%20Manufacturing) Genelux faces multiple manufacturing risks due to the complex, time-consuming, and highly regulated nature of biopharmaceutical production, including difficulties in scaling up, quality control issues, raw material shortages, and contamination, which can lead to delays and increased costs - The manufacture of biopharmaceutical products, especially viral immunotherapies, is complex, time-consuming, highly regulated, and costly, with risks in production, quality control, and supply chain[301](index=301&type=chunk)[302](index=302&type=chunk) - Changes in product candidate manufacturing or formulation, such as switching to a mammalian-cell-based system, may result in additional costs, delays, and require regulatory notification or authorization, potentially affecting clinical trial results[306](index=306&type=chunk)[308](index=308&type=chunk) - Failure to comply with cGMP requirements or meet volume demands could lead to delays in development and commercialization, loss of potential revenues, and regulatory enforcement actions[314](index=314&type=chunk)[315](index=315&type=chunk)[316](index=316&type=chunk) - If the company's manufacturing facility is not approved or cannot meet volume requirements, finding alternative facilities or CMOs could significantly delay development and commercialization[310](index=310&type=chunk) [Risks Related to Reliance on Third Parties](index=72&type=section&id=Risks%20Related%20to%20Reliance%20on%20Third%20Parties) Genelux relies heavily on third parties for raw material supply, quality testing, packaging, distribution, and the conduct of preclinical studies and clinical trials, with failures by these third parties risking significant delays, increased costs, and an inability to obtain regulatory approval or commercialize products - The company relies on third parties to supply and quality-test ingredients, components, and to package and distribute products, facing risks like reduced control, termination of agreements, and supply disruptions[319](index=319&type=chunk)[320](index=320&type=chunk) - Reliance on third-party CROs, study sites, and others to conduct preclinical studies and clinical trials reduces control over these activities, and their failure to perform satisfactorily could delay or prevent regulatory approval[323](index=323&type=chunk)[324](index=324&type=chunk) - Collaboration agreements and strategic alliances, such as with Newsoara, may not yield anticipated benefits, and partners may not perform as expected, delay trials, or terminate agreements, impacting development and commercialization[332](index=332&type=chunk)[336](index=336&type=chunk) - Disruptions at the FDA and other government agencies due to funding shortages or global health concerns could hinder their ability to review and approve new products in a timely manner[345](index=345&type=chunk)[347](index=347&type=chunk) [Risks Related to Commercialization](index=79&type=section&id=Risks%20Related%20to%20Commercialization) Genelux faces significant challenges in commercializing any approved product candidates, including establishing effective marketing, sales, and distribution capabilities, achieving market acceptance, and securing adequate coverage and reimbursement from third-party payors, all within an intensely competitive landscape - Successful commercialization of approved product candidates depends on launching sales, obtaining favorable labels, creating market demand, building sales forces, manufacturing sufficient quantities, and securing reimbursement[349](index=349&type=chunk) - The company faces significant competition from major biopharmaceutical companies, specialty firms, and research institutions in cancer immunotherapy, many with greater financial and technical resources[351](index=351&type=chunk)[361](index=361&type=chunk) - Even with marketing approval, products may fail to achieve market acceptance due to physician/patient reluctance to switch, adverse events, cost, or competition, limiting revenue and profitability[367](index=367&type=chunk)[368](index=368&type=chunk) - Estimating the potential market for product candidates is difficult and uncertain, and inaccurate assumptions could lead to smaller actual markets and adversely affect revenues[372](index=372&type=chunk) - Negative developments in immuno-oncology, including adverse events in clinical trials or competitor therapies, could damage public perception of the oncolytic VACV platform and product candidates[373](index=373&type=chunk) [Risks Related to Our Intellectual Property](index=88&type=section&id=Risks%20Related%20to%20Our%20Intellectual%20Property) Genelux's success hinges on protecting its intellectual property, including patents, trade secrets, and trademarks, but faces risks of patent invalidation, infringement claims, difficulties in global enforcement, and challenges in maintaining trade secret confidentiality - Commercial success depends on obtaining and maintaining patent and other intellectual property protection for its technology and product candidates, but the patent positions in biotechnology are highly uncertain and subject to litigation[377](index=377&type=chunk)[378](index=378&type=chunk)[379](index=379&type=chunk) - The patent prosecution process is expensive and complex, and pending applications may not result in meaningful protection, or issued patents may be challenged, invalidated, or circumvented[382](index=382&type=chunk)[380](index=380&type=chunk) - Failure to comply with obligations in license agreements could lead to loss of intellectual property rights critical to the business[386](index=386&type=chunk)[387](index=387&type=chunk) - Protecting trade secrets and know-how is crucial, but confidentiality agreements may be breached, or information independently discovered, impairing competitive position[390](index=390&type=chunk)[391](index=391&type=chunk) - Third parties may allege infringement of their IP rights, leading to costly and time-consuming litigation, potential monetary damages, or forced cessation of development/commercialization[392](index=392&type=chunk) - Protecting IP globally is expensive and challenging, as foreign laws may offer less extensive protection, and compulsory licensing laws could diminish patent value[396](index=396&type=chunk)[397](index=397&type=chunk)[399](index=399&type=chunk) - Changes to patent law, such as the Leahy-Smith Act, or U.S. Supreme Court rulings, could diminish the value of patents and weaken the ability to obtain or enforce IP[402](index=402&type=chunk)[403](index=403&type=chunk) - Patent terms may be inadequate to protect competitive position, and biological product candidates may face biosimilar competition sooner than anticipated due to limited exclusivity periods[412](index=412&type=chunk)[416](index=416&type=chunk) - Inadequate protection of trademarks and trade names could hinder brand recognition and competitive effectiveness[420](index=420&type=chunk)[422](index=422&type=chunk) [Risks Related to Government Regulation](index=99&type=section&id=Risks%20Related%20to%20Government%20Regulation) Genelux is subject to extensive and evolving government regulations, including federal and state healthcare fraud and abuse laws, data privacy laws, and anti-corruption laws, with non-compliance risking substantial penalties and significant uncertainty regarding coverage and reimbursement from third-party payors - Failure to comply with federal and state healthcare laws, including fraud and abuse laws (Anti-Kickback Statute, False Claims Act, HIPAA, Sunshine Act), could result in substantial civil and criminal penalties, exclusion from healthcare programs, and reputational harm[424](index=424&type=chunk)[425](index=425&type=chunk)[426](index=426&type=chunk) - Inadequate coverage, reimbursement, or unfavorable payment rates from government or third-party payors, or competition from less expensive therapies, could limit revenue and profitability[428](index=428&type=chunk)[430](index=430&type=chunk)[431](index=431&type=chunk) - New legislation and regulatory proposals, such as the ACA and IRA (including drug price negotiation and rebates), may increase compliance costs and adversely affect marketability and pricing of products[436](index=436&type=chunk)[437](index=437&type=chunk)[443](index=443&type=chunk) - The company is subject to stringent and evolving U.S. (HIPAA, CCPA, MHMD) and foreign (GDPR, UK GDPR) data privacy and security laws, with non-compliance or security incidents potentially leading to regulatory actions, litigation, fines, and reputational harm[454](index=454&type=chunk)[455](index=455&type=chunk)[457](index=457&type=chunk)[459](index=459&type=chunk)[469](index=469&type=chunk) - Compliance with environmental, health, and safety laws and the U.S. Foreign Corrupt Practices Act (FCPA) is required, with violations potentially leading to fines, penalties, and adverse business consequences[470](index=470&type=chunk)[450](index=450&type=chunk)[453](index=453&type=chunk) [Risks Related to Our Business and Operations](index=109&type=section&id=Risks%20Related%20to%20Our%20Business%20and%20Operations) Genelux's operations are highly dependent on key personnel, and the inability to attract and retain qualified talent could hinder business strategy, while managing organizational growth, potential future acquisitions, and adverse macroeconomic conditions pose significant risks - The company is highly dependent on key personnel, including its President, CEO, and Chairman; failure to attract, motivate, and retain highly qualified personnel could impede business strategy and R&D objectives[473](index=473&type=chunk)[474](index=474&type=chunk)[475](index=475&type=chunk) - Expanding the organization will require managing growth effectively, including hiring additional personnel and improving operational/financial controls, with potential difficulties disrupting operations[478](index=478&type=chunk) - Future acquisitions or strategic partnerships may increase capital requirements, dilute stockholders, incur debt, and subject the company to integration and unknown liability risks[482](index=482&type=chunk)[483](index=483&type=chunk) - Unfavorable market and economic conditions, including prolonged downturns, could adversely affect the ability to raise capital and strain suppliers[484](index=484&type=chunk) - Public health crises (e.g., pandemics) could materially disrupt preclinical studies and clinical trials, causing delays in patient enrollment, site initiation, and supply chains[486](index=486&type=chunk)[489](index=489&type=chunk) - Compromise of information technology systems or data (including sensitive information) due to cyber-attacks, malicious activity, or human error could lead to regulatory investigations, litigation, fines, business disruptions, and reputational harm[490](index=490&type=chunk)[492](index=492&type=chunk)[502](index=502&type=chunk) - The use of product candidates in clinical trials and commercial sale exposes the company to product liability claims, which could result in substantial liabilities, loss of revenue, and reputational damage[506](index=506&type=chunk)[508](index=508&type=chunk) [Risks Related to Our Common Stock](index=119&type=section&id=Risks%20Related%20to%20Our%20Common%20Stock) Genelux's common stock may experience volatility and lack sustained liquidity, leading to potential losses for investors, with operating results expected to fluctuate, and future stock sales and issuances potentially diluting existing ownership - An active, liquid, and orderly trading market for common stock may not be sustained, leading to difficulties in selling shares quickly or at market price[520](index=520&type=chunk) - Operating results are subject to quarterly fluctuations, making future predictions difficult, and failure to meet investor/analyst expectations could cause stock price declines[521](index=521&type=chunk)[523](index=523&type=chunk) - The market price of common stock may be volatile and fluctuate substantially due to various factors, including clinical trial results, regulatory developments, competition, and macroeconomic conditions[524](index=524&type=chunk)[528](index=528&type=chunk)[531](index=531&type=chunk) - The company does not intend to pay dividends on common stock, so returns are limited to stock value appreciation[534](index=534&type=chunk) - Principal stockholders and management own a significant percentage of stock, enabling them to exert substantial control over matters requiring stockholder approval[535](index=535&type=chunk) - Future sales and issuances of common stock or rights to purchase common stock, including under equity incentive plans, could result in additional dilution of existing stockholders' ownership[539](index=539&type=chunk)[542](index=542&type=chunk) - As an 'emerging growth company' and 'smaller reporting company,' reduced reporting requirements may make common stock less attractive to some investors, potentially leading to a less active trading market and more volatile stock price[543](index=543&type=chunk)[546](index=546&type=chunk) - Provisions in the company's organizational documents and Delaware law could make an acquisition more difficult and prevent attempts by stockholders to replace management[547](index=547&type=chunk)[548](index=548&type=chunk)[550](index=550&type=chunk) [Item 1B. Unresolved Staff Comments](index=126&type=section&id=Item%201B.%20Unresolved%20Staff%20Comments) This section states that the company has no unresolved comments from the SEC staff regarding its filed reports - The company has no unresolved staff comments[568](index=568&type=chunk) [Item 1C. Cybersecurity](index=126&type=section&id=Item%201C.%20Cybersecurity) This section outlines Genelux's cybersecurity risk management and governance, employing external consultants and internal processes to identify, assess, and mitigate threats, with Board oversight and dedicated teams for incident response [Risk management and strategy](index=126&type=section&id=Risk%20management%20and%20strategy) Genelux implements various information security processes, including engaging external cybersecurity consultants, to identify, assess, and manage material risks from cybersecurity threats, integrating these efforts into its overall enterprise risk management program - Genelux implements information security processes to identify, assess, and manage cybersecurity threats to its critical computer networks, services, and data[569](index=569&type=chunk) - The company engages external cybersecurity and IT consultants to monitor threats, analyze reports, conduct scans, and perform third-party threat assessments[570](index=570&type=chunk) - Cybersecurity risk management is integrated into the company's overall enterprise risk management program and includes vulnerability management, disaster recovery, network security, employee training, and cybersecurity insurance[571](index=571&type=chunk)[572](index=572&type=chunk) - A vendor management program is in place to manage cybersecurity risks associated with third-party service providers[574](index=574&type=chunk) [Governance](index=131&type=section&id=Governance) The Board of Directors, through its Audit Committee, oversees Genelux's cybersecurity risk management, with a dedicated Cybersecurity Risk Management Team responsible for implementation, incident preparation, and reporting to senior management and the Board - The Board of Directors, with the Audit Committee, oversees the company's cybersecurity risk management processes[577](index=577&type=chunk) - A Cybersecurity Risk Management Team, including the General Counsel and external consultants, is responsible for implementing and maintaining these processes[578](index=578&type=chunk) - Cybersecurity incidents are escalated to the CFO and CEO, who work with the Incident Response Team, and certain incidents are reported to the Audit Committee[580](index=580&type=chunk) [Item 2. Properties](index=131&type=section&id=Item%202.%20Properties) Genelux leases its corporate headquarters in Westlake Village, California (4,050 sq ft), two facilities in San Diego, California (7,569 sq ft for manufacturing/lab, 6,755 sq ft for future lab/offices), and a business office in Redlands, California (1,884 sq ft) - Corporate headquarters are in Westlake Village, California (**4,050 sq ft**, lease expires July 2027)[582](index=582&type=chunk) - Two facilities are leased in San Diego, California: a **7,569 sq ft** facility for manufacturing and translational science laboratory, and a **6,755 sq ft** facility for future laboratory and administrative offices. Both leases expire in October 2030 with five-year extension options[582](index=582&type=chunk) - A business office is located in Redlands, California (**1,884 sq ft**) on a month-to-month lease[582](index=582&type=chunk) [Item 3. Legal Proceedings](index=131&type=section&id=Item%203.%20Legal%20Proceedings) Genelux Corporation is not currently involved in any material legal proceedings, but acknowledges the potential for future legal proceedings, claims, investigations, and government inquiries arising in the ordinary course of its business - The company is not currently the subject of any material legal proceeding[584](index=584&type=chunk) - Future involvement in legal proceedings, claims, investigations, and government inquiries is possible in the ordinary course of business, including those related to intellectual property, data privacy, and contractual rights[584](index=584&type=chunk) [Item 4. Mine Safety Disclosures](index=131&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to Genelux Corporation - This item is not applicable[585](index=585&type=chunk) [PART II](index=132&type=section&id=PART%20II) [Item 5. Market for Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities](index=132&type=section&id=Item%205.%20Market%20for%20Registrant's%20Common%20Equity,%20Related%20Stockholder%20Matters%20and%20Issuer%20Purchases%20of%20Equity%20Securities) This section provides information on Genelux's common stock, which began trading on the Nasdaq Capital Market under 'GNLX' following its IPO in January 2023, with approximately 1,026 stockholders of record as of March 13, 2025, and no intention to pay dividends [Market Information](index=132&type=section&id=Market%20Information) Genelux's common stock, with a par value of $0.001 per share, is traded on The Nasdaq Capital Market under the symbol 'GNLX', with trading commencing on January 26, 2023, following its initial public offering - Common stock is traded on The Nasdaq Capital Market under the symbol 'GNLX'[587](index=587&type=chunk) - Trading commenced on January 26, 2023, after the initial public offering (IPO)[587](index=587&type=chunk) [Holders of Record](index=132&type=section&id=Holders%20of%20Record) As of March 13, 2025, Genelux Corporation had approximately 1,026 stockholders of record for its common stock - As of March 13, 2025, there were approximately **1,026 stockholders of record** of the company's common stock[588](index=588&type=chunk) [Dividend Policy](index=132&type=section&id=Dividend%20Policy) Genelux Corporation has never declared or paid cash dividends on its common stock and does not anticipate doing so in the foreseeable future, intending to retain all available funds for business development - The company has never declared or paid cash dividends on its common stock[589](index=589&type=chunk) - Genelux intends to retain all available funds and future earnings for business development and expansion, and does not anticipate paying cash dividends in the foreseeable future[589](index=589&type=chunk) [Securities Authorized for Issuance under Equity Compensation Plans](index=132&type=section&id=Securities%20Authorized%20for%20Issuance%20under%20Equity%20Compensation%20Plans) Information regarding securities authorized for issuance under equity compensation plans is incorporated by reference from Item 12 of Part III of this Annual Report on Form 10-K - Information about equity compensation plans is incorporated by reference from Item 12 of Part III[590](index=590&type=chunk) [Recent Sales of Unregistered Securities](index=132&type=section&id=Recent%20Sales%20of%20Unregistered%20Securities) This section states that there have been no recent sales of unregistered securities - No recent sales of unregistered securities[591](index=591&type=chunk) [Purchases of Equity Securities by the Issuer and Affiliated Purchasers](index=132&type=section&id=Purchases%20of%20Equity%20Securities%20by%20the%20Issuer%20and%20Affiliated%20Purchasers) This section states that there were no purchases of equity securities by the issuer or affiliated purchasers - Not applicable[592](index=592&type=chunk) [Item 6. Reserved](index=132&type=section&id=Item%206.%20Reserved) This item is reserved and contains no information - This item is reserved[593](index=593&type=chunk) [Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations](index=133&type=section&id=Item%207.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) This section provides management's perspective on Genelux's financial condition and results of operations for the years ended December 31, 2024 and 2023, highlighting recurring losses, significant accumulated deficit, and ongoing need for substantial additional funding [Overview](index=133&type=section&id=Overview) Genelux is a late clinical-stage biopharmaceutical company focused on oncolytic viral immunotherapies, with Olvi-Vec as its lead candidate, having incurred significant operating losses and an accumulated deficit of $251.4 million as of December 31, 2024, and requiring substantial additional funding - Genelux is a late clinical-stage biopharmaceutical company developing oncolytic viral immunotherapies, with Olvi-Vec as its lead product candidate[595](index=595&type=chunk) - The company has incurred significant operating losses since inception, with net losses of **$29.9 million in 2024** and **$28.3 million in 2023**, and an accumulated deficit of **$251.4 million** as of December 31, 2024[598](index=598&type=chunk) - Genelux expects to continue incurring significant and increasing expenses and operating losses, requiring substantial additional funding to support development, manufacturing, regulatory approval, and potential commercialization[598](index=598&type=chunk)[599](index=599&type=chunk)[600](index=600&type=chunk) [Recent Developments](index=134&type=section&id=Recent%20Developments) Genelux recently completed an underwritten public offering on M

Group 1 - Genelux Corporation (GNLX) has experienced a significant decline of 29.7% over the past four weeks, but it is now in oversold territory, indicating a potential trend reversal [1] - The Relative Strength Index (RSI) for GNLX is currently at 29.16, suggesting that the heavy selling pressure may be exhausting itself [5] - There is strong consensus among Wall Street analysts that GNLX will report better earnings than previously predicted, with a 33% increase in the consensus EPS estimate over the last 30 days [7] Group 2 - GNLX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, indicating a strong potential for a turnaround [8]

Financial Position - As of December 31, 2024, Genelux Corporation estimates its cash, cash equivalents, and short-term investments to be approximately $30.9 million[4]. - The Company has not yet completed its financial close process for the quarter and year ended December 31, 2024, and the preliminary cash estimate is subject to change[4]. - The corporate presentation made available on March 25, 2025, includes forward-looking statements regarding the Company's financial position and clinical trial outcomes[5]. Clinical Trials - In a Phase 1b clinical trial, 71% of evaluable participants (5 out of 7) achieved disease control with Olvi-Vec immunochemotherapy, showing tumor reductions ranging from 24% to 79%[11]. - The FDA indicated that a clinically meaningful progression-free survival advantage could support traditional approval for Olvi-Vec in treating platinum-resistant/refractory ovarian cancer[12]. - The Company anticipates reporting interim results from the Phase 2 VIRO-25 trial in the second half of 2025[14]. - Topline results from the Phase 3 OnPrime/GOG-3076 trial are expected to be reported in the first half of 2026[13]. - Treatment-related adverse events in the Olvi-Vec trial were mostly mild to moderate, with no maximum tolerated dose reached to date[8]. - The Company plans to provide an interim readout of updated data from the ongoing clinical trial in the second half of 2025[10]. - The FDA recommended a pre-BLA meeting to discuss next steps following the completion of the trial[12].

Group 1 - Genelux Corporation announced the pricing of an underwritten offering of 3,000,000 shares of its common stock at $3.50 per share, expecting gross proceeds of $10.5 million before deductions [1][2] - The net proceeds from the offering will be utilized for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec [2] - The offering is expected to close on or about March 26, 2025, subject to customary closing conditions [2] Group 2 - Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [4] - Olvi-Vec is currently being evaluated in two U.S.-based clinical trials: a Phase 3 trial for platinum-resistant ovarian cancer and a Phase 2 trial for non-small-cell lung cancer [4] - The company utilizes its proprietary CHOICE™ platform to develop an extensive library of oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec [4]

Core Insights - Olvi-Vec shows promise as a platinum resensitizing agent for various solid tumors, particularly in platinum-relapsed or platinum-refractory extensive small cell lung cancer [1][3][10] - The ongoing Phase 1b trial indicates a favorable safety profile and preliminary anti-tumor activity, with a 71% disease control rate observed [5][7][8] Company Overview - Genelux Corporation is a late clinical-stage immuno-oncology company focused on developing oncolytic immunotherapies, with Olvi-Vec as its leading candidate [15] - Newsoara BioPharma Co., Ltd. is a pre-commercial-stage biopharmaceutical company collaborating with Genelux on the Olvi-Vec clinical trials [16] Clinical Trial Details - The Olvi-Vec-SCLC-202 trial is a Phase 1b/2 study assessing the safety, tolerability, pharmacokinetics, and efficacy of Olvi-Vec in patients with extensive small cell lung cancer [10][12] - The trial is currently enrolling patients in China, with Shanghai Chest Hospital as the lead clinical site [10] Safety and Efficacy Findings - The systemic administration of Olvi-Vec demonstrated a manageable safety profile, with treatment-related adverse events primarily mild to moderate [5][6] - In the initial dose escalation cohorts, 71% of participants achieved disease control, with significant tumor reductions noted in several cases [7][8] Future Directions - Ongoing evaluation of Phase 1b results will inform the design of the Phase 2 portion of the clinical trial [9][13] - Genelux plans to provide updates on trial progress through future publications and conference presentations [4]

Core Viewpoint - Genelux Corporation has received positive feedback from the U.S. FDA regarding the ongoing OnPrime/GOG-3076 Phase 3 trial for Olvi-Vec, which may support traditional approval for the treatment of platinum resistant/refractory ovarian cancer [1][4] Group 1: FDA Meeting and Trial Insights - The FDA meeting aimed to clarify the requirements for traditional approval of Olvi-Vec, focusing on the ongoing OnPrime/GOG-3076 trial [2] - The FDA indicated that an interim analysis of overall survival should be planned alongside the primary progression-free survival analysis, which could support traditional approval if a clinically meaningful PFS advantage is shown without a decrease in OS [3] - The FDA recommended that Genelux request a pre-BLA meeting to discuss topline safety and efficacy data after the trial's completion [3] Group 2: Trial Design and Patient Population - The OnPrime/GOG-3076 trial is a multi-center, randomized, open-label Phase 3 study evaluating Olvi-Vec in combination with platinum-doublet and bevacizumab against physician's choice of chemotherapy and bevacizumab in patients with PRROC [5] - The trial includes patients who are platinum resistant/refractory and have undergone at least three prior lines of therapy, with no cap on previous treatments [6] - The trial aims to enroll enough patients to achieve 127 events, with primary and secondary endpoints focusing on progression-free survival and overall survival, respectively [5] Group 3: Olvi-Vec Overview - Olvi-Vec is a proprietary modified oncolytic vaccinia virus developed by Genelux for treating various cancers, showing potential to infect and kill tumor cells while eliciting an anti-tumor immune response [7] - The drug has been administered to over 150 patients in previous clinical trials, demonstrating good tolerability and clinical benefits [7] - Olvi-Vec has received Fast Track designation from the FDA for treating platinum resistant/refractory ovarian cancer [7] Group 4: Company Background - Genelux Corporation is a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [8] - In addition to the OnPrime/GOG-3076 trial, Olvi-Vec is being evaluated in two other clinical studies targeting platinum resensitization in non-small-cell lung cancer and small cell lung cancer [9]

Company Overview - Genelux Corporation is a late-stage clinical biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [6] - The company's most advanced product candidate, Olvi-Vec, is currently being evaluated in a Phase 3 trial for platinum-resistant/refractory ovarian cancer [6] Leadership Appointment - Matthew Pulisic has been appointed as the new Chief Financial Officer of Genelux, effective January 30, 2025 [1] - Pulisic brings over 19 years of finance and commercial experience in the biopharmaceutical industry, having held senior roles across the United States, Europe, and Asia [2][3] - His previous role was Vice President of Finance at Arrowhead Pharmaceuticals, where he contributed to the company's financial direction and operational improvements [3] Financial Strategy - Pulisic expressed excitement about joining Genelux and aims to advance the company's financial strategy and enhance shareholder value [4] - As part of his appointment, he received an inducement award of stock options to purchase 275,000 shares at an exercise price of $3.95 per share, vesting over four years [5]

Company Overview - Genelux Corporation is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for aggressive and difficult-to-treat solid tumors [3] - The company's lead candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a modified strain of the vaccinia virus [3] Clinical Programs - Olvi-Vec is currently being evaluated in a Phase 3 registrational trial (OnPrime/GOG-3076) for platinum-resistant/refractory ovarian cancer, comparing its efficacy and safety in combination with platinum-doublet + bevacizumab against physician's choice of chemotherapy and bevacizumab [3] - The company is also conducting a Phase 1b/2 trial in small-cell lung cancer (SCLC) and a Phase 2 trial in non-small cell lung cancer (NSCLC) [2] Upcoming Events - Thomas Zindrick, President, CEO, and Chairman of the Board, will participate in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024 [1] - The session will be moderated by Emily Bodnar, a biotech equity research analyst, and will begin at 11:00 a.m. ET [2]